טקדה מסכימה למכור נכסי OTC ולא ליבתיים לאסינו תמורת יותר מ-200 מיליון דולר אמריקני

Takeda Pharmaceutical Company Limited הודיעה היום שהתקשרה בהסכם למכירת תיק נכסים נבחרים של תרופות OTC (ללא מרשם) ועם מרשם במספר מדינות במזרח הקרוב, המזרח התיכון ואפריקה (NEMEA) שביחידה העסקית שוקי צמיחה ומתעוררים שלה ל- Acino תמורת שווי כולל שעולה על 200 מיליון דולר אמריקני. זאת העסקה השלישית בשנת הכספים 2019 שמקדמת את האסטרטגיה של טקדו להתמקד בתחומים עסקיים שליבתיים לצמיחה שלה בטווח הארוך ולאפשר הפחתת מינוף מהירה אחרי שרכשה את שייר.

Transaction accelerates deleveraging

Agreement simplifies portfolio in Takeda’s NEMEA region

OSAKA, Japan, 15 October 2019, (BUSINESS WIRE):

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa (NEMEA) countries within its Growth and Emerging Markets Business Unit to Acino for a total value in excess of $200 million USD. This is the third transaction in FY19 that furthers Takeda’s strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire.

“The divestment of non-core assets sold in NEMEA represents the continued execution of our strategy to optimize our portfolio, invest in the defined core business areas, and accelerate our progress toward reaching our target leverage ratio,” said Costa Saroukos, Chief Financial Officer, Takeda.

While these products continue to play important roles in meeting patient needs, they are primarily outside of Takeda's chosen business areas – Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience – core to its global long-term growth.

“Takeda remains committed to this region, as we continue our work in accelerating access to our life-changing portfolio of innovative products to meet the needs of patients. We will do this via our commercial activities and Takeda’s Access to Medicines program,” said Ricardo Marek, President, Growth and Emerging Markets Business Unit, Takeda. "We are confident that Acino is best positioned to provide uninterrupted access and supply of the divested products to patients.”

Takeda intends to use the proceeds from this divestiture to reduce debt and continue to deleverage towards its target of 2.0x net debt/adjusted EBITDA over the next three to five years. Takeda is committed to rapid deleveraging driven by strong cash flow and divestiture proceeds, while also simplifying its portfolio.

Transaction Details

Takeda has agreed to sell a portfolio of approximately 30 select prescription pharmaceutical and OTC products sold in the NEMEA region to Acino, a Swiss pharmaceutical company headquartered in Zurich, with a clear focus on selected markets in the Middle East, Africa, the CIS Region, and Latin America. The following key countries are included in the agreement: Egypt, Saudi Arabia, South Africa, Turkey, Ukraine and United Arab Emirates, as well as other countries.

Under the terms of the agreement, Acino will acquire the rights, title, and interest to the products in the portfolio exclusive to these countries. It is anticipated that primarily sales and marketing professionals supporting the portfolio will transition to Acino at closing of the transaction. The parties will also enter into a multi-year manufacturing and supply agreement, under which Takeda will continue to manufacture the products on behalf of Acino.

The transaction is expected to close in Q4 FY19 (January - March 2020), subject to the satisfaction of customary closing conditions including receipt of applicable antitrust approvals. Until then, these products will continue to be made available by Takeda.

Takeda is being advised by BofA Securities (financial advisor), White & Case (legal advisor), and Deloitte (financial consultant) in this transaction.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20191014005742/en/

Contacts

Investor Relations:
Takashi Okubo
+81-(0)3-3278-2306
[email protected]

Media Inquiries:
Sandy Rodriguez
Head, Integration & Divestiture Communications
[email protected]

Vince Docherty
Head, Communications, GEM Business Unit
[email protected]

Kazumi Kobayashi (Japan)
+81 (0)3-3278-2095
[email protected]

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית Business Wire